SERS characterization of colorectal cancer cell surface markers upon anti‐EGFR treatment

Colorectal cancer (CRC) is the third most diagnosed and the second lethal cancer worldwide. Approximately 30–50% of CRC are driven by mutations in the KRAS oncogene, which is a strong negative predictor for response to anti‐epidermal growth factor receptor (anti‐EGFR) therapy. Examining the phenotyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Nana, Pedersen, Bernadette, Shklovskaya, Elena, Rizos, Helen, Molloy, Mark P., Wang, Yuling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190927/
https://www.ncbi.nlm.nih.gov/pubmed/37323700
http://dx.doi.org/10.1002/EXP.20210176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10190927/
https://www.ncbi.nlm.nih.gov/pubmed/37323700
http://dx.doi.org/10.1002/EXP.20210176

Ejemplares similares